Cargando…
Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial
AIMS: To investigate the difference in the efficacy among dipeptidyl peptidase-4 (DPP-4) inhibitors in Chinese adults with newly diagnosed diabetes. MATERIALS AND METHODS: In a multicenter, randomized study, we enrolled adults who were either treatment naive or off prior anti-hyperglycemic therapy f...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432871/ https://www.ncbi.nlm.nih.gov/pubmed/30822272 http://dx.doi.org/10.1530/EC-18-0523 |
_version_ | 1783406214414073856 |
---|---|
author | Zhou, Xiao-jun Ding, Lin Liu, Jia-xin Su, Le-qun Dong, Jian-jun Liao, Lin |
author_facet | Zhou, Xiao-jun Ding, Lin Liu, Jia-xin Su, Le-qun Dong, Jian-jun Liao, Lin |
author_sort | Zhou, Xiao-jun |
collection | PubMed |
description | AIMS: To investigate the difference in the efficacy among dipeptidyl peptidase-4 (DPP-4) inhibitors in Chinese adults with newly diagnosed diabetes. MATERIALS AND METHODS: In a multicenter, randomized study, we enrolled adults who were either treatment naive or off prior anti-hyperglycemic therapy for at least 3 months. Eligible patients had hemoglobin A1c (HbA1c) concentrations of 6.5–9.5%. Three hundred patients had been randomly allocated to sitagliptin 100 mg, once daily; vildagliptin 50 mg, twice daily and saxagliptin 5 mg, once daily for 12 weeks. Patients and investigators were masked to treatment assignment. The primary endpoint was change from baseline in HbA1c at week 12. This study was completed and registered with ClinicalTrials.gov, number NCT 01703637. RESULTS: Totally 277 patients were enrolled in the final analysis, and 93 patients received sitagliptin, 94 received vildagliptin and 90 received saxagliptin. Compared with baseline, adjusted mean differences in change from baseline HbA1c at week 12 were −0.50% (95% CI: −0.20 to −0.90), −0.65% (95% CI: −0.40 to −1.40), −0.70 (95% CI: −0.50 to −1.00) for sitagliptin, vildagliptin and saxagliptin group, respectively. The overall HbA1c-lowering effect was similar for all three selected DPP-4 inhibitors after adjustment for age and baseline HbA1c. Notably, in secondary outcome analysis, patients in vildagliptin group showed a significant decrease in total cholesterol levels, compared with participants in sitagliptin and saxagliptin groups. No significant between-group difference was shown in adverse events (AE). CONCLUSIONS: The overall HbA1c-lowering effect and incidence of AE were similar for sitagliptin, vildagliptin and saxagliptin in Chinese adults with newly diagnosed diabetes. |
format | Online Article Text |
id | pubmed-6432871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-64328712019-03-27 Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial Zhou, Xiao-jun Ding, Lin Liu, Jia-xin Su, Le-qun Dong, Jian-jun Liao, Lin Endocr Connect Research AIMS: To investigate the difference in the efficacy among dipeptidyl peptidase-4 (DPP-4) inhibitors in Chinese adults with newly diagnosed diabetes. MATERIALS AND METHODS: In a multicenter, randomized study, we enrolled adults who were either treatment naive or off prior anti-hyperglycemic therapy for at least 3 months. Eligible patients had hemoglobin A1c (HbA1c) concentrations of 6.5–9.5%. Three hundred patients had been randomly allocated to sitagliptin 100 mg, once daily; vildagliptin 50 mg, twice daily and saxagliptin 5 mg, once daily for 12 weeks. Patients and investigators were masked to treatment assignment. The primary endpoint was change from baseline in HbA1c at week 12. This study was completed and registered with ClinicalTrials.gov, number NCT 01703637. RESULTS: Totally 277 patients were enrolled in the final analysis, and 93 patients received sitagliptin, 94 received vildagliptin and 90 received saxagliptin. Compared with baseline, adjusted mean differences in change from baseline HbA1c at week 12 were −0.50% (95% CI: −0.20 to −0.90), −0.65% (95% CI: −0.40 to −1.40), −0.70 (95% CI: −0.50 to −1.00) for sitagliptin, vildagliptin and saxagliptin group, respectively. The overall HbA1c-lowering effect was similar for all three selected DPP-4 inhibitors after adjustment for age and baseline HbA1c. Notably, in secondary outcome analysis, patients in vildagliptin group showed a significant decrease in total cholesterol levels, compared with participants in sitagliptin and saxagliptin groups. No significant between-group difference was shown in adverse events (AE). CONCLUSIONS: The overall HbA1c-lowering effect and incidence of AE were similar for sitagliptin, vildagliptin and saxagliptin in Chinese adults with newly diagnosed diabetes. Bioscientifica Ltd 2019-03-01 /pmc/articles/PMC6432871/ /pubmed/30822272 http://dx.doi.org/10.1530/EC-18-0523 Text en © 2019 The authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (http://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Research Zhou, Xiao-jun Ding, Lin Liu, Jia-xin Su, Le-qun Dong, Jian-jun Liao, Lin Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial |
title | Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial |
title_full | Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial |
title_fullStr | Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial |
title_full_unstemmed | Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial |
title_short | Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial |
title_sort | efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in chinese diabetes: a randomized clinical trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432871/ https://www.ncbi.nlm.nih.gov/pubmed/30822272 http://dx.doi.org/10.1530/EC-18-0523 |
work_keys_str_mv | AT zhouxiaojun efficacyandshorttermsideeffectsofsitagliptinvildagliptinandsaxagliptininchinesediabetesarandomizedclinicaltrial AT dinglin efficacyandshorttermsideeffectsofsitagliptinvildagliptinandsaxagliptininchinesediabetesarandomizedclinicaltrial AT liujiaxin efficacyandshorttermsideeffectsofsitagliptinvildagliptinandsaxagliptininchinesediabetesarandomizedclinicaltrial AT sulequn efficacyandshorttermsideeffectsofsitagliptinvildagliptinandsaxagliptininchinesediabetesarandomizedclinicaltrial AT dongjianjun efficacyandshorttermsideeffectsofsitagliptinvildagliptinandsaxagliptininchinesediabetesarandomizedclinicaltrial AT liaolin efficacyandshorttermsideeffectsofsitagliptinvildagliptinandsaxagliptininchinesediabetesarandomizedclinicaltrial |